MedTrace Logo

Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

NCT01508104 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2017-08-23

No results posted yet for this study

Summary

The purpose of this clinical trial is to determine the effects good or bad of combining BEZ235 along with Everolimus to determine if it is a safe treatment for patients with advanced cancers of different types.

Conditions

Interventions

DRUG

BEZ235

dose escalation 400mg- 1000mg per day

DRUG

Everolimus

dose escalation 2.5 to 5 mg per day

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • John Morris, MD · University of Cincinnati

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-02-28
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01508104 on ClinicalTrials.gov